Show
Sort by
-
- Journal Article
- A1
- open access
Week 48 resistance analyses of the once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials
-
Immediate versus deferred switching from a boosted protease inhibitor-based regimen to a dolutegravir-based regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years : final 96-week results of the NEAT022 study
-
- Journal Article
- A1
- open access
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
-
Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort
-
Towards colourless and coolerless components for low power optical networks (invited)
-
A symmetric 320Gb/s capable, 100km extended reach hybrid DWDM-TDMA PON
-
A review of biaxial test methods for composites
-
Comparison of isolation media for recovery of Burkholderia cepacia complex from respiratory secretions of patients with cystic fibrosis.